March 2021 marks one-year since COVID-19 took over the United States, rattling the U.S. M&A markets, and grinding deals to a virtual standstill. The advent of the virus also profoundly impacted the reps and warranties insurance product, leading insurers in the spring of 2020 to impose special “COVID-19 exclusions” and requiring heightened due diligence around COVID-19 related risks.
But by December 2020, the markets had shifted yet again, turning red-hot, and culminating in a rush of year-end deals and many U.S. transactional risk markets pulling back from blanket COVID-19 exclusions. With vaccines now here and re-openings on the horizon, where are M&A markets and RWI headed now, in hopefully the final stages of the COVID-19?
To talk about these topics and more, Bryan and Gena are joined by Bill Monat, Executive Vice-President and Transactional Risk Solutions Leader at Willis Towers Watson. Known industry-wide as one of the preeminent thought leaders in the RWI space, Bryan, Gena, and Bill engage in a big-picture discussion on COVID-19 and its impact on reps and warranties insurance, touching on topics such as:
• A revisiting of how 2020 started for M&A markets
• A discussion on the immediate impact felt by COVID-19 starting in March 2020
• The advent of the “COVID-19” exclusion on RWI policies and how different markets initially reacted to the virus
• The market rebound in Q4 of 2020 and how RWI placements finished for the year
• The state of the market today in March 2021 and how insurers have evolved on COVID-19 policy language
• Predictions about how the arrival of the vaccine and gradual reopening will impact M&A and RWI
• Looking back at changes that we thought in 2020 were poised to occur and how the virus impacted their trajectory